Skip to main
LFCR
LFCR logo

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical is projected to experience significant growth in its financial performance, with EBITDA expected to rise from $22.1 million in FY26, reflecting a margin of 16.8%, to $27.3 million in FY27, which indicates an improved margin of 19.1%. Furthermore, the company has turned positive in free cash flow, projecting $5.1 million in FY26 and an increase to $6.0 million in FY27. These trends in both profitability and cash flow generation provide a robust foundation for a favorable outlook on Lifecore Biomedical's stock performance.

Bears say

Lifecore Biomedical is projected to experience a market growth that may be slightly below the anticipated 10% for fill/finish services, raising concerns about its ability to capitalize on industry trends. The company's high leverage ratio further exacerbates these concerns, as it indicates a heavier debt burden relative to its earnings potential. Additionally, significant revenue growth is not expected until calendar year 2027, which negatively impacts the company’s financial outlook compared to its peers.

LFCR has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Buy based on their latest research and market trends.

According to 2 analysts, LFCR has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.